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Abstract 
Pharmacology is the study of how drugs interact within the human 
body. The field covers a variety of topics such as pharmaceutical capabilities 
and interactions. Early studies in pharmacology focused on the effects of 
natural substances in the body as a means of therapeutic treatment. Modern 
pharmacology uses computation and modeling as research tools on a cellular 
level. Computational models are useful in almost every scientific and 
engineering discipline especially when practical and ethical considerations 
prevent experimenting with real systems. The models are needed to design 
various parts of the drug discovery process. Computer programs for designing 
compounds is one key area of computational pharmacology. Another area of 
interest are digital repositories for investigating chemical interactions. 
Modern pharmacology now involves using a computational method. This 
paper provides a brief introduction to computational pharmacology. 
 
Keywords: Computational pharmacology, computational drug discovery, 
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Introduction 
As the number of people in the world increases, the number of people 
seeking medical attention for a variety of reasons also increases. The higher 
frequency of diseased individuals has resulted in hospitals, clinics, and other 
medical-related establishments, such as pharmaceutical companies, becoming 
inundated with filed data sets which may include electronic health records of 
patients and clinical reports from drug trials (Bellai, 2011). Rare diseases are 
also more prominent in recent years as seen in the outbreak of the polio-like 
disease, acute flaccid myelitis or AFM, which has paralyzed hundreds of 
American children in the last five years (McKay, 2018). According to the 
Centers for Disease Control and Prevention (CDC), several factors and 
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symptoms have been found in patients; however, all are not found in all 
patients (McKay, 2018). It was believed that the enterovirus D68 or EV-D68 
was the main cause of AFM but results have been inconclusive as all cases do 
not possess this result (Pastula, 2014; Nelson, 2016; Morrey, 2018). There are 
many questions that remain about the disease such as is source and possible 
treatment mechanisms.   
Pharmacology is the study of the interaction between drugs and 
biological systems. This area of science includes topics such as medicine, 
pharmacy, nursing, and dentistry. Two main focus areas are 
pharmacodynamics and pharmacokinetics (Lees, 2004).  Pharmacodynamics 
is defined as the study of the molecular, biochemical, and physiological effects 
of drugs.  Pharmacokinetics is the study of how drugs move through the body 
whether it is the absorption process, drug distribution, and excretion of drugs 
(Lees, 2004).   
Pharmacology can be further subdivided neuropharmacology, 
cardiovascular pharmacology, molecular pharmacology, biochemical 
pharmacology, clinical pharmacology, psychopharmacology, and 
chemotherapy (Weinhart, 2018). Some areas focus on a different part of the 
human body such as the heart, blood vessels, or nervous system. Other areas 
are more concerned with patient treatment such as clinical pharmacology or 
patient psyche such as psychopharmacology.  
Modern pharmacology seeks the usage of computation and modeling 
as research and design tools. Computational and simulation approaches 
provide modeling tools to study biological systems and the effect that drugs 
have on them (Weinhart, 2018). The following text reviews the rapidly 
growing number of fields switching to the usage of computational methods 
and the areas of application.  
 
Computation as a necessity 
Over the years, the advances and success rate in the production of new 
drugs has dwindled in the face of new medical challenges (Cressey, 2011; 
Pammolli, 2011). Most pharmaceutical companies will spend over $1 billion 
in hopes of introducing a new drug to the market (Kaitin, 2010). Due to the 
economic considerations in the development of new drugs, there are concerns 
regarding the suitability of maintaining current approaches in pharmacological 
research (Weinhart, 2018). In short, the experimental methods are expensive. 
Classic medical treatments research focused solely on developing a drug for a 
single purpose or target. Theoretical pharmacologists aim at finding the 
structure—activity relations of a particular drug and predicting the biological 
activity of the drug. Recently, computational analysis emerged as a useful 
approach for drug design and discovery as a predictive model (Vilar, 2014; 
Lui, 2014; Hodos, 2016; Platamia, 2018). 
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Computational calculations supplement theoretical physics and 
experimental physics.  Since most physics problems are difficult to solve 
exactly or may be nonlinear in nature, design is required. Today computation 
is considered as an equal partner with theory and experiment.  
Computation provides a means of studying complex natural 
phenomena that would be too expensive or dangerous to study by direct 
experimentation. As the capabilities of computers increase, computational 
methods and analysis have become crucial in the simulation of physical events 
and engineering systems. Computational experimentation involves computer 
simulation and is often regarded as computer experimentation or simply 
computer modeling. Computational models are useful as these models are 
often implemented in common programming language such as C++, Basic, or 
FORTRAN.  Development of such models can occur using software packages 
such as MATLAB or MATHEMATICA. 
  Many disciplines have undergone a computational methods overhaul 
in the past decades. The recent computational turn has produced several new 
fields of studies including: computational biology, computational chemistry, 
computational mechanics, computational fluid dynamics, computational 
physics, computational electromagnetic, computational humanities, and 
computational finance (Sadiku, 2018). Computation also plays a vital role in 
the pharmacology industry. 
  Computational pharmacology (CP) involves the integrated study of 
pharmacology and computational analysis. This field involves computational 
approaches for the storage of pharmacology analysis and sensitive 
information, management of drug trials, analysis of results, and modeling of 
drug systems. CP allows for probing the mechanisms of drug interactions that 
often occurs in one of the excitable diseases. CP is commonly used as a 
predictive tool for large data sets as seen in modeling drug-to-drug interactions 
(Vilar, 2014). CP has the capability of providing a ‘multi-angled’ approach to 
predicting drug interactions in the body (Hodos, 2016). 
Review of the literature suggests an apparent ‘gap’ between 
experimental and computational methods (Babcok, 2013). Human-based 
models are designed to bridge the gap from basic research to preclinical drug 
testing (Weinhart, 2018). Computational models provide several economic 
advantages for drug development by refining drug design (Lui, 2014). The 




Computational tools are routinely developed to address drug-related 
problems. These tools efficiently assess potential new interactions and predict 
unknown drug-target interaction. One source groups CP applications into three 
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main categories (Hodos, 2016): 1) prediction of drug-to-target interactions, 2) 
prediction and characterization of drug side effects, and 3) repurposing of 
drugs. One study involved a systemic computational pharmacology approach 
using pharmacokinetic modeling that was introduced to investigate the global 
nature of certain drugs such as Traditional Chinese medicine (TCM) (Wu, 
2011). This study proved that CP enhanced understanding of a complex 
system. Another study for CP  utilized the technology in drug repurposing. 
Hodos et. al (2016) hypothesized that CP matrix factorization is an acceptable 
approach in integrating diverse data and determining missing data. 
Drug interaction is often complex and can have a wide range of 
parameters that affect the overall performance of the drug (Boran, 2010; Vilar, 
2014; Hobos, 2016). Additional models have been developed that address 
other drug properties and design parameters such as rate of absorption, 
bioavailability, binding tendencies, metabolism, volume of distribution, and 
other drug interactions. Common methods of developing these statistical 
models include data regression or neural networks (Sliwoski, 2014). 
The next step in evolving CP capabilities is understanding how to 
successfully integrate multiple data sets in a manner that provides 
understanding of human disease (Boran, 2010). One area of interest includes 
performing qualitative and quantitative image analysis of diseases cells. 
Another area includes the analysis and modeling of large genomic and 
proteomic data sets. CP is also useful in designing novel molecular tools to 
probe and perturb cellular function and developing predictive models of 
complex cellular processes. 
The future of computational pharmacology also includes the 
development of personalized medicine applications based on algorithms 
configured for a single individual (Hodos, 2016). This type of technology can 
advance treatment for individuals with diseases that can vary by patient such 
as cancer, sickle cell anemia, or diabetes. For example, diabetic retinopathy is 
a diabetic disease that currently possesses no approved early stage drug 
treatments (Platania, 2018). A recent study by Platiania et. al (2018) has 
utilized a biological based CP to analyze the diabetic retinas in some animals. 
The group deemed the process as a useful biological CP tool and suggested 
that the method was suitable for other pathological investigations. 
 
Conclusion and outlook 
Computational approaches in pharmacology offer a means of 
identifying potential interactions. Computational pharmacology has been 
proven as a useful and effective technique for finding, mining, and predicting 
the properties of Chinese medicine. The method is involved in leading current 
medical advances. Predictive models using multiple parameters have been 
proven successful as the case with Vilar et. al (2014).  
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In spite of the progress in computational pharmacology, several 
challenges remain unsolved. Several diseases, such as cancer, autism, and 
depression, remain without a cure and are, sometimes, not adequately treated. 
The pharmaceutical industry and their regulating bodies have recognized the 
importance of computational pharmacology in today’s society. More 
occurrences of rare diseases, such as the recent acute flaccid myelitis (AFM) 
outbreak in U.S. children, has led to the increasing need for more expertise in 
CP. It is imperative that more universities seek to train graduates will use their 
knowledge of CP to bridge knowledge gaps as members of multidisciplinary 
research groups. The advancement of computation pharmacology is without 
a doubt important to future pharmaceutical discoveries. 
 
References: 
1. Babcock, J.J. (2013). Computational pharmacology of the HERG 
potassium channel, Doctoral Dissertation, Johns Hopkins University. 
2. Bellazzi, R., Diomidous, M., Sarkar, I.N., Takabayashi, K., Ziegler A., 
and A.T. McCray (2011). Data analysis and data mining: current issues 
in biomedical informatics. Meth. Info. Med. 50, p. 536. 
3. Boran, A.D.W. and R. Iyengar (2010). Systems approaches to 
polypharmacology and drug discovery, Curr. Op. Drug Discov. 
Dev., 13(3), pp. 297-309. 
4. Cressey, D. (2011). Traditional drug-discovery model ripe for reform. 
Nature, 471, pp. 17-18. 
5. Hodos, R.A., Kidd, B.A., Khader, S., Readhead, B.P., and J.T. Dudley 
(2016). Computational Approaches to Drug Repurposing and 
Phamacology, Wiley Interdiscip. Rev. Syst. Biol. Med. 8(3), pp. 186-
210. 
6. Kaitin, K.I., (2010). Deconstructing the drug development process: the 
new face of innovation. Clin. Pharmacol. Thera., 87, pp. 356-361. 
7. Lees, P., Cunningham, F.M., and J. Elliott (2004). Principles of 
pharmacodynamics and their applications in veterinary pharmacology. 
J. of Veter. Pharmacol. and Thera., 27(6), pp. 397–414. 
8. Liu, C. (2014). Computational approaches in molecular and systems 
pharmacology: Application to neurosignaling membrane proteins, 
Master’s Thesis, University of Pittsburgh. 
9. McKay, S.L., Lee, A.D., Lopez, A.S., Nix, W.A., Doolin, K.L., 
Keaton, A.A., Spence-Davizon, E., Herlihy, R., Clark, T.A., Hopkins, 
S.E., Pastula, D.M., Sejvar, J., Oberste, M.S., Pallansch, M.A., Patel, 
M., and J.A. Routh  (2018). Increase in Acute Flaccid Myelitis — 
United States, 2018. MMWR Morb Mortal Wkly Rep. 67, pp. 1273–
1275. DOI: http://dx.doi.org/10.15585/mmwr.mm6745e1 
European Scientific Journal March 2019 edition Vol.15, No.9 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
156 
10. Morrey, J.D., Wang, H., Hurst, B.L., Zukor, K., Siddharthan, V., Van 
Wettere, A.J., Sinex, D.G., and E.B. Tarbet (2018). Causation of Acute 
Flaccid Paralysis by Myelitis and Myositis in Enterovirus-D68 
Infected Mice Deficient in Interferon αβ/γ Receptor Deficient Mice. 
Viruses. 10(1), 33-55. 
11. Nelson, G.R., Bonkowsky, J.L., Doll, E.; Green, M., Hedlund, G.L., 
Moore, K.R., and J.F. Bale, Jr. (2016). Recognition and Management 
of Acute Flaccid Myelitis in Children. Pediatr. Neurol. 55, pp. 17–21. 
12. Pammolli, F., Magazzini, L., and M. Riccaboni (2011). The 
productivity crisis in pharamaceutical R&D. Nat. Rev. Drug. Discov. 
10(6), pp. 428-438. 
13. Pastula, D.M., Aliabadi, N., Haynes, A.K., Messacar, K., Schreiner, 
T., Maloney, J., Dominguez, S.R., Davizon, E.S., Leshem, E., Fischer, 
M., et al. (2014). Acute neurologic illness of unknown etiology in 
children—Colorado, August-September 2014. Morb. Mortal. Wkly. 
Rep., 63, 901–902. 
14. Platania, C.B.M., Leggio, G.M., Drago, F., Salomone, S., and C. 
Bucolo (2018). Computational systems biology approach to identify 
novel pharmacological targets for diabetic retinopathy. Biochem. 
Pharmacol. 158, pp. 13-26. 
15. Sadiku, M.N.O., Tembely, M., and S.M. Musa (July 2018). 
Computational statistics,  Inter. J. of Adv. Res. in Comp. Sci. and 
Software Eng.,  8(7), pp. 76-78. 
16. Sliwoski, G., Kothiwale, S., Meiler, J., and E.W. Lowe, Jr. (January 
2014). Computational methods in drug discovery, Pharmacol. Rev, 66, 
pp. 334–395. 
17. Vilar, S., Uriarte, E., Santana, L., Lorberbaum, T., Hripcsuk G., 
Friedman, C., and N.P. Tatonetti (2014). Similarity-based modeling in 
large-scale prediction of drug interactions. Nature Protocols, 9, pp. 
2147-2163. 
18. Weinhart M., Hocke, A., Hippenstiel, S., Kurreck, J., and S. Hedtrich 
(2018). 3D organ models - Revolution in pharmacological research?, 
Pharmacol. Res. Online: https://doi.org/10.1016/j.phrs.2018.11.002. 
19. Wu, D.H. and X.J. Xu (2011). A New Practice: Study on the Molecular 
Mechanism of Traditional Chinese Medicine by Computational 
Pharmacology Methods: Part 1: Pharmacokinetic Modeling and 
Chemical Space Distribution, Letters in Drug Des. & Discov., 8(7), pp. 
652-658. 
 
 
 
  
